Hypophosphatasia Market Poised for Robust Growth Through 2036 as Next-Generation Therapies Advance
Key Insights
AstraZeneca's asfotase alfa (STRENSIQ) posted Q1 2026 revenue of USD 517 million, a 43% increase at constant exchange rates, reflecting sustained global demand as the only approved disease-modifying therapy for hypophosphatasia (search).
Efzimfotase alfa (ALXN1850) demonstrated positive Phase III results and has received both Fast Track and Orphan Drug Designation from the FDA, positioning it as a key next-generation enzyme replacement therapy.
Alesta Therapeutics' oral small-molecule therapy ALE1 advanced into clinical development with Phase I/IIa data expected in H2 2026, backed by a €65 million Series A financing.
The global hypophosphatasia (search) treatment market is undergoing a significant transformation, shifting from a historically supportive-care–driven landscape toward a disease-modifying paradigm anchored by enzyme replacement therapy and a diversifying pipeline of next-generation modalities. According to a comprehensive market analysis from DelveInsight, this ultra-rare genetic metabolic disorder—caused by mutations in the ALPL (search) gene resulting in deficient tissue-nonspecific alkaline phosphatase (TNSALP (search)) activity—is attracting growing investment and innovation from leading pharmaceutical companies including AstraZeneca, AM-Pharma (search), Alesta Therapeutics, and PuREC (search).
The market's current cornerstone, asfotase alfa (STRENSIQ) developed by AstraZeneca, remains the only approved disease-modifying therapy for hypophosphatasia (search). The drug posted Q1 2026 revenue of USD 517 million, representing a 43% increase at constant exchange rates, driven by sustained global demand and continued treatment uptake. Clinical evidence demonstrates improvements in bone mineralization, survival, and functional outcomes, supporting strong adoption in diagnosed patients, particularly those with pediatric-onset disease.
Next-Generation ERTs Advance in Clinical Development
The pipeline is increasingly diversifying with next-generation enzyme replacement therapies aiming to improve upon the limitations of current treatment. As of March 2026, AstraZeneca announced that efzimfotase alfa (ALXN1850) demonstrated positive results from its global Phase III clinical programme in hypophosphatasia (search). The investigational therapy has received both Fast Track Designation and Orphan Drug Designation from the US FDA, underscoring the regulatory recognition of ongoing unmet needs in this patient population.
Ilofotase alfa, another emerging ERT candidate, has been granted Orphan Drug Designation by both the US FDA and the European Medicines Agency. These designations highlight the importance of the European market, where increasing utilization of genetic testing and growing recognition of adult-onset hypophosphatasia (search) are contributing to market expansion.
Oral Small-Molecule Therapy Represents Paradigm Shift
Alesta Therapeutics is advancing ALE1, an investigational oral small-molecule therapy targeting PPi accumulation, which represents a potential departure from injectable enzyme replacement. In January 2025, the company closed an oversubscribed €65 million Series A financing round led by Frazier Life Sciences and Droia Ventures to advance its oral small-molecule pipeline for rare diseases. ALE1 advanced into clinical development in 2025, with initial Phase I/IIa data anticipated in the second half of 2026. The company secured Clinical Trial Application clearances in both the United Kingdom and Germany, initiating the second part of the ALE1 Phase I/IIa study and planning patient dosing in the first half of 2026.
Beyond Enzyme Replacement: Novel Mechanistic Approaches
The therapeutic landscape is expanding beyond enzyme replacement to include several novel mechanistic strategies. ENPP1 inhibitors targeting PPi accumulation, MSC-based regenerative therapies such as REC-01, and gene therapy programs are being explored as potentially longer-term or curative solutions. These modalities collectively reflect a broader shift toward addressing the root metabolic dysregulation in hypophosphatasia (search) rather than merely managing symptoms.
Diagnostic Advances Expand Treatable Population
The diagnosed prevalence of hypophosphatasia (search) is increasing, primarily due to enhanced clinical awareness and wider use of genetic testing for ALPL (search) mutations. Historically underdiagnosed—especially in adult and milder forms—hypophosphatasia is now being more frequently identified as physicians recognize hallmark features such as persistently low ALP levels and atypical fractures. This trend is expected to expand the treatable patient pool across major markets.
Regional Market Dynamics
North America, led by the United States, is anticipated to maintain the largest market share, supported by strong clinical awareness, advanced genetic testing infrastructure, established reimbursement frameworks, and the widespread availability of asfotase alfa through the OneSource access program. Europe, including Germany, France, Italy, Spain, and the United Kingdom, represents another key regional market, with regulatory designations for pipeline therapies further highlighting the region's importance. Japan, where asfotase alfa has been approved and available since 2015, is also included as a key geography in the 7MM analysis.
Despite the clinical benefits of asfotase alfa, significant treatment gaps remain due to lifelong injectable administration, high treatment burden, and limited accessibility across mild and adult patient populations. The DelveInsight report notes that the market will likely remain concentrated around existing ERT use until late-stage innovations mature, though increasing diagnostic awareness, expansion of genetic testing, and gradual pipeline diversification are expected to support steady long-term growth across the 7MM through 2036.